Do you routinely check tumor genomics, including POLE status for new endometrial cancers?
How does the presence of specific mutations affect your adjuvant treatment planning or patient counseling?
Given POLE mutation status can currently only be determined by next generation sequencing and incurs significantly added cost, when do you routinely order this testing given the 90 day global period for reimbursement?
Answer from: at Academic Institution
This is an evolving question! My first comment is if it's not going to impact your treatment decisions, probably best not to order. But with increasing data to suggest the POLE mutated tumors may not require as intense therapy, it would certainly be reasonable to order - especially as a "tie-breaker...
Sign in or Register to read more